Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00132652 · ClinicalTrials.gov registry record · Phase 3
Switching Therapy From Lamivudine to Telbivudine Versus Continued Lamivudine in Adults With Chronic Hepatitis B
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
NCT00132652 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 240 participants.
The verdict
NCT00132652, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
Study Summary
This study is being conducted to compare the safety and effectiveness of switching treatment from lamivudine to telbivudine (LdT) against continued lamivudine treatment. Results from patients who were taking lamivudine and then switched to telbivudine will be compared with the results from patients who continued on lamivudine alone.
Interventions
- DRUG Lamivudine
- DRUG Telbivudine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2005-02 |
| Est. Completion | 2006-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00132652
The ClinicalTrials.gov registry entry for NCT00132652 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lamivudine is the first listed.
NCT00132652 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00132652 about?
NCT00132652 is a clinical study titled "Switching Therapy From Lamivudine to Telbivudine Versus Continued Lamivudine in Adults With Chronic Hepatitis B". This study is being conducted to compare the safety and effectiveness of switching treatment from lamivudine to telbivudine (LdT) against continued lamivudine treatment. Results from patients who were taking lamivudine and then switched to telbivudine will be compared with the results from patients ...
What is the current status of trial NCT00132652?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2005-02. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00132652?
The interventions under investigation include: Lamivudine (DRUG), Telbivudine (DRUG).
Who is sponsoring clinical trial NCT00132652?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.